RIZREDY
Live / Allowed — Second extension granted (statement of use) (as of 12 Jan 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 17 Jul 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98652186
- Mark type
- Word mark
- Filed
- 17 Jul 2024
- Published for opposition
- 10 Dec 2024
- Attorney of record
- Danielle Rivera
Goods and services
- Class 005 — Pharmaceuticals: Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
Owner
- Johnson & Johnson, New Brunswick, NJ
- Johnson & Johnson, New Brunswick, NJ
Prosecution history
- 13 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Jan 2026 — SOU EXTENSION 2 GRANTED
- 12 Jan 2026 — SOU EXTENSION 2 FILED
- 12 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 26 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Jul 2025 — SOU EXTENSION 1 GRANTED
- 25 Jul 2025 — SOU EXTENSION 1 FILED
- 25 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Feb 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 10 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Dec 2024 — PUBLISHED FOR OPPOSITION
- 04 Dec 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Nov 2024 — ASSIGNED TO EXAMINER
- 17 Jul 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED